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4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase
activity and expression in breast cancer cells
Bin Su , Serena M. Mershon, Laura A. Stonerock,
Robert W. Curley Jr., Robert W. Brueggemeier
Introduction
4-Hydroxyphenylretinamide (4HPR) is one of the most stud-
ied retinoid analogs for use in cancer prevention. It is found
to inhibit the growth of breast, prostate, and ovarian cancers in
animal models [1–5]. 4HPR has potent preventive effects in a
rodent mammary tumor model and less toxicity than retinoic
acid, and has been tested in a large breast cancer prevention trial
[6]. Retinoids bind to retinoic acid receptors (RAR) and retinoid
X receptors (RXR), which bind to specific DNA sequences to
regulate gene expression [7]. However, as a synthetic retinoid
analog, 4HPR minimally binds RXR receptors and seems to have
only moderate affinity for both the RAR and RAR receptor
compared to all-trans retinoic acid (RA) [8,9]. This result points
to a mode of action of 4HPR that is at least partially independent
of the RAR or RXR. So far, a definitive mechanism by which
4HPR exerts its chemo-preventive effect on mammary tumor
growth remains unclear.
Approximately, two-thirds of breast cancers are termed
hormone-dependent breast cancers, contain estrogen receptors
(ER), and require estrogen for tumor growth. Aromatase activ-
ity in tumor or surrounding tissue plays a significant role in
promoting this type of tumor growth due to the local produc-
tion of estrogen, and thus aromatase is an important target
in the treatment of ER positive breast cancer [10]. Recently,
there are several studies reporting that 4HPR inhibits both
the expression and enzyme activity of aromatase in breast
cancer cells and placental cells [11,12]. In addition, RA can
induce aromatase activity in breast cancer and placental cells
at the transcriptional level [13,14]. This induction apparently
is from the RA agonist effect with RAR and RXR. We
hypothesize that investigation of RA and 4HPR analogs might
discover potent RAR antagonist which can effectively down
regulate aromatase activity and expression in breast cancer
cells.
A number of these analogs were synthesized (Fig. 1) and
investigated in breast cancer cells and also a microsomal aro-
matase enzyme assay. In addition, CYP19 gene expression in
breast cancer cells was checked after the treatment with the
4HPR analogs. Unexpectedly, some of the derivatives dramati-
cally up regulated aromatase activity and expression in several
breast cancer cell lines. Only one analog significantly decreased
aromatase activity in all three breast cancer cell lines tested. To
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Fig. 1. Synthesis of 4HPR analogs [15].
our surprise, 4HPR decreased aromatase activity in a cell selec-
tive manner and only slightly inhibited microsomal aromatase
activity in our studies.
Materials and methods
Reagents
Radiolabeled [1-3H]-androst-4-ene-3,17-dione was
obtained from NEN Life Science Products (Boston, MA).
4HPR and analogs were synthesized according to the published
procedure [15]. For in vitro experiments, these agents at various
concentrations were dissolved in DMSO. Trypsin, TRIzol, and
all enzymes were obtained from Invitrogen (Carlsbad, CA).
Radioactive samples were counted on a LS6800 liquid scintil-
lation counter (Beckman, Palo Alto, CA). Scintillation solution
3a70B was obtained from Research Prospect International Corp.
(Mount Prospect, IL). (±)-Aminoglutethimide (AG), NADP+
and glucose-6-phosphate dehydrogenase were purchased from
Sigma (St. Louis, MO). Human tissue (placenta) was obtained
through OSUCCC Tissue Procurement under IRB-approved
protocols OSU#2002H0105.
Cell culture
SK-BR-3, MCF-7 and MDA-MB-231 cells were obtained
from ATCC (Rockville, MD). Cell cultures were maintained in
phenol red-free custom media (MEM, Earle’s salts, 1.5× amino
acids, 2× non-essential amino acids, l-glutamine, 1.5× vita-
mins, Gibco BRL) supplemented with 10% fetal bovine serum
(FBS), 2 mM l-glutamine and 20 mg/L gentamycin. FBS was
heat inactivated for 30 min in a 56 ◦C water bath before use.
Cell cultures were grown at 37 ◦C, in a humidified atmosphere
of 5% CO2 in a Hereaus CO2 incubator. For all experiments,
cells were plated in either T-25 flasks or 100 mm plates and
grown to subconfluency before treatment.
Tritiated water-release assay in cells
Measurement of aromatase enzyme activity in cells was
based on the tritium water-release assay [16]. Cells in T-25
flasks or 100 mm plates were treated with DMSO (control),
4HPR and analogs for 24 h. Cells were then incubated for
6 h with fresh media containing drugs and 2Ci [1-3H]-
androst-4-ene-3,17-dione (100 nM). Subsequently, the reaction
mixture was removed, and proteins were precipitated using 10%
trichloroacetic acid at 42 ◦C for 20 min. After a brief centrifuga-
tion, the media was extracted three times with an equal amount
of chloroform to extract unused substrate, and the aqueous layer
subsequently treated with 1% dextran-treated charcoal. After
centrifugation, a 250-L aliquot containing the product was
counted in 5 mL of liquid scintillation mixture. Each sample
was run in triplicate and results were corrected for blanks and
for the cell contents of culture flasks. Results were expressed as
picomoles of 3H2O formed per hour incubation time per million
cells (pmol/h/106 cells). To determine the amount of live cells
in each flask, the cells were trypsinized and analyzed using the
diphenylamine DNA assay adapted to a 96-well plate.
Cell viability analysis
The effect of 4HPR derivatives on breast cancer cell viability
was assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide assay in six replicates. Cells
were grown in custom media in 96-well, flat-bottomed plates
for 24 h, and were exposed to various concentrations of 4HPR
derivatives dissolved in DMSO (final concentration ≤ 0.1%) in
culture media for 24 h. Controls received DMSO vehicle at a
concentration equal to that in drug-treated cells. The medium
was removed, replaced by 200L of 0.5 mg/mL of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide in
fresh media, and cells were incubated in the CO2 incubator
at 37 ◦C for 2 h. Supernatants were removed from the wells,
and the reduced 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide dye was solubilized in 200L/well
DMSO. Absorbance at 570 nm was determined on a plate
reader.
Preparation of human placental microsomes
Human placenta was processed immediately after delivery
from The Ohio State University Hospitals at 4 ◦C. The placenta
was washed with normal saline, and connective and vascu-
lar tissue was removed. Microsomes were prepared from the
remaining tissue using the method developed in our laboratory.
Microsomal suspensions were stored at −80 ◦C until required.
Tritiated water-release assay with human placental
microsomes
Inhibition of human placental aromatase was determined
by monitoring the amount of tritiated water released as the
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enzyme converts [1-3H] androst-4-ene-3,17-dione to estrone
[17]. Aromatase activity assays were carried in 0.1 M potas-
sium phosphate buffer (pH 7.0) with 5% propylene glycol. All
samples contained a NADPH regenerating system consisting of
2.85 mM glucose-6-phosphate, 1.8 mM NADP+ and 1.5 units
of glucose-6-phosphate dehydrogenase. Samples contained
100 nM androst-4-ene-3, 17-dione (400,000–450,000 dpm).
Reactions were initiated with the addition of 50g microsomal
protein. The total incubation volume was 2.0 mL. Incubations
were allowed to proceed for 15 min in a shaking water bath
at 37 ◦C. Reactions were quenched by the addition of 2.0 mL
of chloroform. Samples were then vortexed and centrifuged
for 5 min and the aqueous layer was removed. The aqueous
layer was subsequently extracted twice in the same manner
with 2.0 mL chloroform. A 0.5 mL aliquot of the final aque-
ous layer was combined with 5 mL 3a70B scintillation cocktail
and the amount of radioactivity was determined. Each sample
was run in triplicate and background values were determined
with microsomal protein inactivated by boiling.
RNA extraction
Total RNA was isolated using the TRIzol reagent accord-
ing to the manufacturer’s protocol. Total RNA pellets were
dissolved in DNase, RNase-free water and quantitated using a
spectrophotometer. The quality of RNA samples was determined
by electrophoresis through agarose gels and staining with ethid-
ium bromide; the 18S and 28S rRNA bands were visualized
under ultraviolet light.
cDNA synthesis
Isolated total RNA (2g) was treated with DNase I Ampli-
fication grade, according to the recommended protocol to
eliminate any DNA before reverse transcription. Treated total
RNA was denatured at 65 ◦C for 5 min in the presence of
2.5 ng/L random hexamers and 0.5 mM dNTP mix. The
samples were snap-cooled on ice and centrifuged briefly. Com-
plementary DNA (cDNA) was synthesized using Superscript
II reverse transcriptase according to the recommended proto-
col. Briefly, the reactions were conducted in the presence of 1×
First-Strand Buffer and 20 mM DTT at 42 ◦C for 50 min and con-
sequently inactivated at 70 ◦C for 15 min. The cDNA generated
was used as a template in real-time PCR reactions.
Real-time PCR with Taqman assay
Real-time PCR was performed using the OpticonTM 2 sys-
tem from MJ Research (Waltham, MA). For the CYP19 total
gene the PCR reaction mixture consisted of Taqman® Univer-
sal PCR Master Mix (Applied Biosystems), 600 nM of CYP19
primer (sense: 5′-TGT CTC TTT GTT CTT CAT GCT ATT
TCT C-3′; antisense: 5′-TCA CCA ATA ACA GTC TGG ATT
TCC-3′); 250 nM Taqman probe (6FAM 5′-TGC AAA GCA
CCC TAA TGT TGA AGA GGC AAT-3′TAMRA) (Invitro-
gen), and 2.0L of each cDNA sample in a final volume of
20L. For the 18S house keeping total gene the PCR reac-
tion mixture consisted of Taqman® Universal PCR Master Mix
(Applied Biosystems), 500 nM of 18S primer (sense: 5′-CAG
TTC ATA CAG CGG AAC ACT G-3′; antisense: 5′-TTT GCT
GGA GAA CAG GGC TG-3′); 50 nM Taqman probe (6FAM
5′-TGC TGG CAC CAG ACT TGC CCT C-3′TAMRA) (Invit-
rogen), and 2.0L of each cDNA sample in a final volume of
20L. The Taqman probes for aromatase and 18S were designed
to anneal to a specific sequence of the aromatase and 18S gene
correspondingly between the forward and the reverse primers.
Cycling conditions were 50 ◦C for 2 min and 95 ◦C for 10 min,
followed by 50 cycles at 95 ◦C for 15 s and 60 ◦C for 1 min.
Statistical analysis
Statistical and graphical information was determined using
GraphPad Prism software (GraphPad Software Incorporated)
and Microsoft Excel (Microsoft Corporation). Determination of
IC50 values were performed using nonlinear regression analy-
sis. Statistically significant differences were calculated with the
two-tailed unpaired Student’s t-test and p values reported at 95%
confidence intervals.
Results
4HPR analogs regulate aromatase activity in SK-BR-3
breast cancer cells
4HPR decreases both microsomal aromatase and cellular aro-
matase activity [11]. We propose that 4HPR analogs might be
more effective in suppression of aromatase. A 5M aromatase
screening assay in SK-BR-3 breast cancer cells was performed
with these compounds. Unfortunately, most of the derivatives
and even 4HPR itself did not decrease aromatase activity in
SK-BR-3 breast cancer cells (Table 1). Only compound 19 sig-
nificantly suppressed aromatase activity. To our surprise, two
analogs (compounds 7, 20) dramatically stimulate cellular aro-
matase activity, which is similar to RA [13]. Though 4HPR
binds to retinoic acid receptors very weakly, we hypothesize that
these two 4HPR analogs might bind to retinoic acid receptors as
agonist to stimulate aromatase expression. Further studies con-
firmed that both the stimulation and suppression of aromatase
occur dose dependently (Fig. 2A) and the agents tested in the
assays do not cause any cell cytotoxicity which rule out the pos-
sibility that compound 19 decreases cellular aromatase activity
because of cytotoxic effect (Fig. 2B).
4HPR analogs regulate aromatase activity in MCF-7
and MDA-MB-231 breast cancer cells
Although 4HPR did not affect aromatase in SK-BR-3 cells, it
and compound 19 significantly decreased aromatase activity in
MCF-7 breast cancer cells (Fig. 3A). However, 4HPR at 5M
caused significant cell cytotoxicity (Fig. 3B), and part of the
suppression of aromatase activity might come from the cyto-
toxic effect. Compounds 7, 20 and RA all significantly induced
cellular aromatase activity (Fig. 3A) and did not cause cell cyto-
toxicity.
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Table 1
4HPR analogs regulate aromatase activity in SK-BR-3 breast cancer cells
Compounds number Chemical structure Aromatase activity with the
compounds treatment (5M)
in SK-BR-3 breast cancer
cells (percentage of control)
R1 R2 R3 R4 R5 R6
4HPR H H OH H H H 110 ± 3
1 OH H H CH3 H H 111 ± 4
2 OH H H H CH3 H 105 ± 12
3 OH H H C(CH3)3 H H 83 ± 12
4 OH CO2H H H H H 86 ± 10
5 OH H CO2H H H H 112 ± 6
6 OH H SO2H H H H 97 ± 2
7* OH H CH3 H H H 195 ± 10
8 OH H CO2CH3 H H H 99 ± 20
9 CH3 OH H H H H 106 ± 23
10 H OH CO2CH3 H H H 132 ± 17
11 H OH CH3 H H H 129 ± 14
12 CH3 H OH CH3 H H 106 ± 14
13 H Cl OH Cl H H 138 ± 12
14 H NO2 OH H H H 131 ± 14
15 H H OCH3 H H H 112 ± 11
16 H H Cl H H H 89 ± 1
17 H H CH3 H H H 128 ± 11
18 H Cl Cl H H H 91 ± 4
19* H H OH H H CH3 33 ± 11
20* 173 ± 34
All-trans retinoic acid* 190 ± 17
SK-BR-3 cells were treated with indicated compounds at 5M and aromatase activity was measured as described in Section 2. The results were normalized against
a control treatment with vehicle. Each value represents the mean results of three independent determinations. *p < 0.05 vs. DMSO treatment by unpaired t test (n= 3).
In addition, the effect of these agents on aromatase occurred
in the similar trend in MDA-MB-231 breast cancer cells and
they did not cause any cell cytotoxicity (Fig. 4). However, the
suppression of aromatase activity by compound 19 in MDA-
MB-231 cells was not as significant as it in SK-BR-3 and MCF-7
breast cancer cells (Fig. 4). We think that low aromatase activ-
ity in MDA-MB-231 cells may be one of the reasons, because
the suppression effect cannot be clearly observed with the low
enzyme activity.
4HPR decrease microsomal aromatase activity
It has been reported that 4HPR inhibits microsomal aro-
matase extracted from JAR cells [12]. We did the study with
placenta microsomal aromatase and found that 4HPR does
directly inhibit enzyme activity. This may also be one of the
mechanisms by which 4HPR suppresses aromatase activity in
MCF-7 cells. However, compound 19 did not inhibit aromatase
enzyme activity at all although it has very similar structure
to 4HPR (Fig. 5), which suggests that compound 19 does not
directly inhibit cellular aromatase activity.
Compound 7, 20 and RA stimulate CYP19 gene
expression
Since compound 7, 20 and RA all induce aromatase activ-
ity in the three breast cancer cell lines tested and it has been
reported that RA stimulates CYP19 gene expression in placental
cells [13], we hypothesized that compound 7, 20 and RA might
stimulate aromatase expression in breast cancer cells as well.
Investigations found that compound 7, 20 and RA all induced
CYP19 gene expression in these three breast cancer cell lines
(Fig. 6), although some results are not statistically significant.
This is consistent with the cellular aromatase assay results.
4HPR did not affect aromatase expression in any of the
cell studied. Although compound 19 significantly decreased
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Fig. 2. 4HPR analogs and RA regulate aromatase activity in SK-BR-3 cells in a
dose dependent manner, no cytotoxic effect was observed. (A) Aromatase study:
SK-BR-3 cells were treated with indicated compounds at indicated concentra-
tions and aromatase activity was measured as described in Section 2. *p < 0.05,
**p < 0.005 vs. DMSO treatment by unpaired t test (n = 3). (B) Cell cytotoxic-
ity study: SK-BR-3 cells were treated with indicated compounds at indicated
concentrations and cell viability was measured by MTT assay as described in
Section 2.
aromatase activity in all three breast cancer cell lines, it only sup-
presses CYP19 gene expression in MCF-7 cells (Fig. 6B). Since
it does not directly inhibit aromatase enzyme activity (Fig. 5),
we propose that compound 19 might suppress cellular aromatase
with a post transcriptional mechanism. This can explain that
it decreases aromatase activity in MDA-MB-231 and SK-BR-
3 cells without suppression of their CYP19 gene expression.
Due to the double mechanisms in MCF-7 cells, compound 19 is
very potent in suppression of aromatase activity in this cell line
(Fig. 3A).
Discussion
Retinoids are natural and synthetic analogs of vitamin A
that are involved in the regulation of many biological func-
tions such as cellular differentiation and proliferation. RA and
4HPR are considered potential drug candidates for treatment and
prevention of several cancers and 4HPR is less toxic than RA.
Aromatase represents a novel target for the potential therapeutic
actions of 4HPR in ER positive breast cancer treatment from
recent studies [11,12].
Fig. 3. 4HPR analogs and RA regulate aromatase activity in MCF-7 cells in
a dose dependent manner, no cytotoxic effect was observed. (A) Aromatase
study: MCF-7 cells were treated with indicated compounds at indicated concen-
trations and aromatase activity was measured as described in Section 2. *p < 0.05,
**p < 0.005 vs. DMSO treatment by unpaired t test (n= 3). (B) Cell cytotoxicity
study: MCF-7 cells were treated with indicated compounds at indicated concen-
trations and cell viability was measured by MTT assay as described in Section
2. **p < 0.005 vs. DMSO treatment by unpaired t test (n = 6).
Unfortunately, most 4HPR derivatives used in this study do
not suppress aromatase activity in breast cancer cells. In fact, two
compounds (7 and 20) significantly induced aromatase activity
in all three cell lines. Further studies exhibit that compound 7
and 20 also stimulate CYP19 gene expression in these cells. It
has been well studied that RA is a potent retinoic acid receptor
agonist and stimulates aromatase expression in placental cells
[8,13]. In addition, other RXR and RAR ligands dramatically
stimulate aromatase in MCF-7 breast cancer cells [14], which
proves that the retinoic acid receptor plays an important role
in regulating aromatase expression in breast cancer cells. Our
studies further confirm that the retinoic acid receptor agonist
RA stimulates aromatase expression in these three breast cancer
cell lines. Due to the fact that compound 7 and 20 stimulated aro-
matase expression in breast cancer cells which is similar to RA,
we propose that these two compounds may also bind to retinoic
receptor as agonist. Further studies are needed to quantify the
binding affinity of compound 7 and 20 with retinoic receptors.
Interestingly, 4HPR only decreased aromatase activity in
MCF-7 breast cancer cells in our study. It has been also reported
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Fig. 4. 4HPR analogs and RA regulate aromatase activity in MDA-MB-231 cells
in a dose dependent manner, no cytotoxic effect was observed. (A) Aromatase
study: MDA-MB-231 cells were treated with indicated compounds at indicated
concentrations and aromatase activity was measured as described in Section 2.
*p < 0.05, **p < 0.005 vs. DMSO treatment by unpaired t test (n = 3). (B) Cell
cytotoxicity study: MDA-MB-231 cells were treated with indicated compounds
at indicated concentrations and cell viability was measured by MTT assay as
described in Section 2.
Fig. 5. Inhibition of microsomal aromatase activities by 4HPR and com-
pound19. Each data bar represents the mean results of three independent
determinations. Error bars represent standard error. AG is used as a posi-
tive control. **p < 0.005, ***p < 0.0001 vs. DMSO treatment by unpaired t test
(n = 3).
Fig. 6. Real-time RT-PCR analysis of CYP19 mRNA expression in SK-BR-3,
MCF-7 and MDA-MB-231 cells after treatment with the agents. (A) SK-BR-3
cells, (B) MCF-7 cells and (C) MDA-MB-231 cells. Cells were treated for 24 h
with the test agents at 5M, and total RNA was isolated. Results are expressed
as means of CYP19 (normalized to 18S rRNA) ± SEM. *p < 0.05 vs. control by
unpaired t test (n = 3).
that 4HPR suppresses aromatase in JEG-3 placental cells, which
is accomplished with ceramide increase. However, it does not
affect aromatase induced by dexamethasone and cholera toxin
in MDA-MB-231 cells [12]. The signalling molecule ceramide
has also been previously implicated as a negative regulator of
aromatase activity [18]. The result demonstrates that 4HPR
may suppress aromatase activity in a cell selective manner via
ceramide by a receptor independent mechanism. This has been
further proved by another study in MCF-7 cells in which 4HPR
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decreases cellular aromatase activity without affecting CYP19
gene expression at the same concentration [11].
Compound 19 suppresses aromatase activity in all three
breast cancer cell lines without direct enzyme inhibition. The
results suggest that this compound suppresses cellular aromatase
activity mainly via a non-genomic mechanism, though it also
decreases CYP19 gene expression in MCF-7 cells. Besides
direct inhibition, agents that target protein phosphorylation also
decrease cellular aromatase activity in bone, brain, and breast
cancer cells in a rapid non-genomic mechanism [19–21]. It has
been reported that the PI3 kinase (PI3K) inhibitor LY294002
and mitogen-activated protein kinase (MAPK) inhibitor U0126
decrease aromatase activity by blocking the cell phosphorylation
pathways without affecting CYP19 gene expression [21]. This
could be a possible mechanism that compound 19 decreases cel-
lular aromatase activity with a non-genomic action. Further work
is needed to search for the molecular target(s) of compound 19.
However, the dual functions in suppressing aromatase in MCF-7
cell line make this compound a good lead to design more effect
agents to target aromatase.
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